Drug Insight: endothelin-receptor antagonists for pulmonary arterial hypertension in systemic rheumatic diseases (Q36577383)

15 August 2017

1 reference

title

Drug Insight: endothelin-receptor antagonists for pulmonary arterial hypertension in systemic rheumatic diseases (English)

1 reference

15 August 2017

main subject

arterial hypertension

1 reference

1

Marc Humbert

1 reference

15 August 2017

2

Gérald Simonneau

1 reference

15 August 2017

publication date

1 December 2005

1 reference

Nature Clinical Practice Rheumatology

15 August 2017

published in

1 reference

15 August 2017

volume

1

1 reference

15 August 2017

issue

2

1 reference

15 August 2017

page(s)

93-101

1 reference

Clinical classification of pulmonary hypertension.

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0048

Survival in patients with primary pulmonary hypertension. Results from a national prospective registry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0048

Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0048

Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0048

Pulmonary hypertension in systemic sclerosis: risk factors for progression and consequences for survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0048

The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0048

Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0048

Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0048

Treatment of pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0048

Nitric oxide pathway and phosphodiesterase inhibitors in pulmonary arterial hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0048

Endothelin receptor antagonists in pulmonary arterial hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0048

Endothelin and endothelin receptor antagonists in systemic rheumatic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0048

A novel potent vasoconstrictor peptide produced by vascular endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0048

Serum endothelin-1 concentrations and cold provocation in primary Raynaud's phenomenon

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0048

Raised plasma concentrations of endothelin-1 in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0048

Expression of endothelin-1 in the lungs of patients with pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0048

Endothelin-1 in idiopathic pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0048

Fibroblast matrix gene expression and connective tissue remodeling: role of endothelin-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0048

Cardiac fibrosis occurs early and involves endothelin and AT-1 receptors in hypertension due to endogenous angiotensin II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0048

Role of endothelin in fibrosis and anti-fibrotic potential of bosentan

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0048

Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0048

Effects of the oral endothelin-receptor antagonist bosentan on echocardiographic and doppler measures in patients with pulmonary arterial hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0048

Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension: a 1-year follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0048

Survival with first-line bosentan in patients with primary pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0048

Clinical efficacy of sitaxsentan, an endothelin-A receptor antagonist, in patients with pulmonary arterial hypertension: open-label pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0048

Sitaxsentan therapy for pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0048

STRIDE 1: effects of the selective ET(A) receptor antagonist, sitaxsentan sodium, in a patient population with pulmonary arterial hypertension that meets traditional inclusion criteria of previous pulmonary arterial hypertension trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0048

Sustained symptomatic, functional, and hemodynamic benefit with the selective endothelin-A receptor antagonist, sitaxsentan, in patients with pulmonary arterial hypertension: a 1-year follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0048

Ambrisentan therapy for pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0048

Cellular and molecular pathobiology of pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0048

Comparative analysis of clinical trials and evidence-based treatment algorithm in pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0048

Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0048

Differential effects of stable prostacyclin analogs on smooth muscle proliferation and cyclic AMP generation in human pulmonary artery

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0048

An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0048

Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0048

Pulmonary Fibrosis and Chronic Lung Inflammation in ET-1 Transgenic Mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0048

Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0048

Pulmonary hypertension in systemic sclerosis: an analysis of 17 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0048

7 January 2021

Effects of separate and combined ETA and ETB blockade on ET-1-induced constriction in perfused rat lungs

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0048

7 January 2021

Big endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0048

7 January 2021

Ninth edition of the G.B. Morgagni Awards Program

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0048

7 January 2021

Plasma endothelin concentrations in patients with pulmonary hypertension associated with congenital heart defects. Evidence for increased production of endothelin in pulmonary circulation

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0048

7 January 2021

Relation of elevated plasma endothelin in congenital heart disease to increased pulmonary blood flow

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0048

7 January 2021

Plasma endothelin-1 levels in patients with left-to-right shunt with or without pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0048

7 January 2021

Effects of endothelins on cardiac and vascular cells: new therapeutic target for the future?

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0048

7 January 2021

Bosentan therapy for pulmonary arterial hypertension

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0048

7 January 2021

Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0048

7 January 2021

Identifiers

DOI

10.1038/NCPRHEUM0048

1 reference

15 August 2017

1 reference